Here, we present a longer follow‐up (median 35.2 months) of the pooled datasets to compare long‐term outcomes of second‐line (with 1 prior line of therapy) versus later‐line (with >1 prior lines of therapy) zanubrutinib treatment in R/R MCL patients, which will also help to determine if the early start of BTK inhibitor monotherapy would benefit R/R MCL patients more than its use in later‐line. This evidence concerns the gene BTK and mantle cell lymphoma.